Bleomycin-induced Pulmonary Function Abnormalities

Wolkowicz, Jeffrey; Sturgeon, J.; Rawji, M; Chan, Charles K.

doi:10.1378/chest.101.1.97

Cited by 52 publications

(20 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Это было подтверждено и в пос ледующих исследованиях [37]. Основываясь на обус ловленных блеомицином гистологических измене ниях у животных, считали, что нарушение диффузии окиси углерода вызвано непосредственно блеомици ном.…”

Section: обзорыunclassified

Pulmonary lesions due to drug therapy of Hodgkin's lymphoma

Даниленко¹,

Шахтарина²

2013

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

show abstract

Section: обзорыunclassified

Pulmonary lesions due to drug therapy of Hodgkin's lymphoma

Даниленко¹,

Шахтарина²

2013

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

show abstract

“…Bleomycin is a well-recognized pulmonary toxin (26)(27)(28)(29)(30)(31)(32)(33). Less data is available for other pulmonary agents.…”

Section: Agents' Toxicities To Normal Tissuementioning

confidence: 99%

The Impact of Induction Chemotherapy and the Associated Tumor Response on Subsequent Radiation-Related Changes in Lung Function and Tumor Response

Mao

Koçak

Zhou

et al. 2007

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Purpose-To assess the impact of induction chemotherapy, and associated tumor shrinkage, on the subsequent radiation-related changes in pulmonary function and tumor response.Methods and Materials-As part of a prospective IRB-approved study, 91 evaluable patients treated definitively with thoracic RT for unresectable lung cancer were analyzed. The rates of RTassociated pulmonary toxicity and tumor response were compared in the patients with and without pre-RT chemotherapy. In the patients receiving induction chemotherapy, the rates of RT-associated pulmonary toxicity and tumor response were compared in the patients with and without a response (modified RECIST criteria) to the pre-RT chemotherapy. Comparisons of the rates of improvements in PFTs post-RT, dyspnea requiring steroids, and percent declines in PFTs post-RT were compared in patient subgroups using Fisher's exact test, analysis of variance, and linear or logistic regression.Results and conclusion-The use of pre-RT chemotherapy appears to increase the rate of radiation-induced pneumonitis (p=0.07-0.01), but has no consistent impact on changes in PFTs. The degree of induction-chemotherapy-associated tumor shrinkage is not associated with the rate of subsequent-RT-associated pulmonary toxicity. The degree of tumor response to chemotherapy is not related to the degree of tumor response to RT. Additional study is needed to better clarify this issue.

show abstract

“…Most notably, there may be a high incidence of clinically silent lung injury. The toxicity may be monitored by the decrease in diffusion capacity for carbon monoxide (>10-15% from baseline), which has been found to be the most sensitive indicator of subclinical pulmonary damage from chemotherapeutics [23]. In a prospective clinical study, paclitaxel and carboplatin led to significant but clinically silent decrease (!20% of start values) in diffusion capacity for carbon monoxide, persisting for 5 months after completion of chemotherapy [24].…”

Section: Pulmonary Toxicitymentioning

confidence: 99%